<DOC>
	<DOCNO>NCT00005599</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness bryostatin 1 paclitaxel treat patient locally advance metastatic esophageal cancer stomach cancer .</brief_summary>
	<brief_title>Bryostatin 1 Plus Paclitaxel Treating Patients With Locally Advanced Metastatic Esophageal Cancer Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete partial response rate patient unresectable metastatic esophageal cancer carcinoma gastroesophageal junction treat sequential paclitaxel bryostatin 1 . - Determine toxicity regimen patient population . - Determine survival patient treatment regimen . - Determine quality life patient treat regimen . - Examine pre- post-treatment tissue biopsy marker apoptosis select patient . OUTLINE : This multicenter study . Patients receive paclitaxel IV 1 hour day 1 bryostatin 1 IV 24 hour day 2 weekly 2 week . Courses repeat every 28 day absence unacceptable toxicity disease progression . Quality life assess baseline , course 1 2 , every 2 course thereafter . PROJECTED ACCRUAL : A total 19-33 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma adenocarcinoma esophagus carcinoma gastroesophageal ( GE ) junction If tumor extend GE junction proximal stomach , 50 % tumor must involve esophagus GE junction No gastric cancer minor involvement GE junction distal esophagus Locally advance consider surgically unresectable metastatic Measurable disease Accurately measure least 1 dimension least 20 mm conventional technique least 10 mm spiral CT scan No truly nonmeasurable lesion : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No history active angina No myocardial infarction within past 6 month No history significant ventricular arrhythmia require medication antiarrhythmic Wellcontrolled atrial fibrillation standard management allow Pulmonary : DLCO least 60 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation No preexisting neurotoxicity grade 3 great No serious concurrent infection nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy No concurrent psychiatric disorder would preclude study compliance No active malignancy within past 5 year except : Nonmelanoma skin cancer Carcinoma situ cervix History T1a b prostate cancer ( detect incidentally transurethral resection prostate [ TURP ] comprise less 5 % resected tissue ) provide prostatespecific antigen remain normal since TURP removal HIV negative No concurrent medical condition would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : Recovered prior chemotherapy No 1 prior neoadjuvant adjuvant regimen esophageal cancer No prior taxanes esophageal cancer No prior bryostatin 1 esophageal cancer No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow provided recent evidence disease progression indicator lesion within prior radiation field Recovered prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>